Melanoma
Showing 1 - 25 of 1,172
Profiling of Circulating Immune Cells to Uncover Response
Not yet recruiting
- Melanoma
- (no location specified)
Nov 23, 2023
Melanoma, NSCLC Trial (Evaluation of ctDNA using the F1T after 1 year of immunotherapy)
Not yet recruiting
- Melanoma
- Non-small Cell Lung Cancer
- Evaluation of ctDNA using the F1T after 1 year of immunotherapy
- (no location specified)
Nov 24, 2023
Gut and Tumor Microbiome in Advanced ER-positive and
Not yet recruiting
- Breast Cancer
- Melanoma
- Observation
- (no location specified)
Nov 6, 2023
Tumor Infiltrating Lymphocytes, Safety, Melanoma Trial in Beijing (GC101 TIL)
Recruiting
- Tumor Infiltrating Lymphocytes
- +4 more
- GC101 TIL
-
Beijing, ChinaBeijing Cancer Hospital
Nov 7, 2023
NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Pembrolizumab co-formulated with hyaluronidase
- Pembrolizumab
- (no location specified)
Oct 19, 2023
Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)
Withdrawn
- Advanced Solid Tumor
- +9 more
- (no location specified)
Oct 16, 2023
Melanoma Trial in Beijing (IBI363)
Not yet recruiting
- Melanoma
- IBI363
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Oct 7, 2023
Skin Cancer, Melanoma Trial in Stockholm (AI assistance)
Enrolling by invitation
- Skin Cancer
- Melanoma
- AI assistance
-
Stockholm, SwedenKarolinska University Hospital
Oct 6, 2023
Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)
Active, not recruiting
- Tumor Skin
- +2 more
- OBX-115
-
Orlando, Florida
- +1 more
Sep 28, 2023
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,
Not yet recruiting
- Diffuse Astrocytoma, IDH-Mutant
- +20 more
- NEO212 Oral Capsule
- +8 more
- (no location specified)
Sep 18, 2023
3 in Vivo Microscopic Imaging Techniques for Diagnosis of
Completed
- Basal Cell Carcinoma
- +5 more
- Fluorescence-Advanced videodermatoscopy
- +2 more
-
Saint Etienne, FranceChu de Saint Etienne
Sep 14, 2023
Melanoma, Breast Cancer, Oncology Trial in Saint-Petersburg
Active, not recruiting
- Melanoma
- +7 more
-
Saint-Petersburg, Russian FederationN. N. Petrov Research Institute of oncology
Sep 12, 2023
ful Mutations in Solid Tumor Characterized by Next Generation
Recruiting
- Solid Tumor
- +13 more
-
Aviano, Pordonone, ItalyIRCCS, Centro di Riferimento Oncologico (CRO) di Aviano
Sep 8, 2023
Melanoma Trial in Beijing (tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin)
Not yet recruiting
- Melanoma
- tunlametinib
- paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 15, 2023
Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)
Not yet recruiting
- Melanoma
- Fluzoparib Camrelizumab Temozolomide
- (no location specified)
Aug 9, 2023
Head Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma Trial in Scottsdale, Chapel Hill (TSC-204-A0201, TSC-204-C0702,
Not yet recruiting
- Head and Neck Cancer
- +20 more
- TSC-204-A0201
- +4 more
-
Scottsdale, Arizona
- +1 more
Aug 3, 2023
Sarcoma, Carcinoma, Digestive Cancer Trial in Linyi (Recombinant oncolytic herpes simplex virus type 1 (R130))
Recruiting
- Sarcoma
- +9 more
- Recombinant oncolytic herpes simplex virus type 1 (R130)
-
Linyi, Shandong, ChinaLinyi Central Hospital
Jul 25, 2023
Head Neck Cancer, Cervical Cancer, Endometrial Cancer Trial (ILB-2109, Toripalimab)
Not yet recruiting
- Head and Neck Cancer
- +9 more
- (no location specified)
Jul 12, 2023
Melanoma Trial (V940, Pembrolizumab, Placebo)
Not yet recruiting
- Melanoma
- V940
- +2 more
- (no location specified)
Jul 12, 2023
